The mechanisms of pubertal timing in humans are not well defined and are thought to be mediated through complex interactions of neural and endocrine signals resulting in stimulation of the GnRH pulse regulator. Although marked changes in pubertal onset are seen in disorders of GH, IGF-I, leptin, insulin, and adrenal androgens ([@B1]), the physiological roles of these hormones in regulating pubertal timing are uncertain. Earlier age at menarche has been associated with low birth weight, rapid weight gain during infancy, and childhood obesity, suggesting a role of developmental programming in the regulation of pubertal timing ([@B2]). However, the hormonal changes that potentially mediate these associations have not been defined. The aim of this study was to identify childhood hormonal predictors of earlier menarche that are independent of body size.

Subjects and Methods
====================

Participants
------------

The Avon Longitudinal Study of Parents and Children (ALSPAC) is a Bristol (UK)-based prospective study of 14,541 newborns recruited from all pregnancies with expected dates of delivery between April 1991 and December 1992 and is described in detail elsewhere ([@B3]). Ethics approval for the study was obtained from the ALSPAC Law and Ethics Committee and the Local Research Ethics Committee. Signed consent was obtained from a parent, and verbal assent was obtained from the child.

Data and sample collection
--------------------------

Anthropometric measurements and an overnight fasting blood sample were collected at a research clinic at age 8 yr. Height was measured using a Harpenden stadiometer (Holtain Ltd., Dyfed, UK), body weight was measured using electronic scales, and waist circumference was measured midway between the lowest rib and the iliac crest by tape measure (Harpenden anthropometric tapes, Holtain Ltd.). Body mass index (BMI) was calculated as weight (kilograms)/height (meters)^2^. At a later research clinic at mean age 12.9 yr (interquartile range, 12.8--13.0 yr), girls were asked whether they had started their menstrual periods and, if so, at what age. Some missing data on age at menarche at this clinic were imputed from data collected at ages 11 and 13 yr. Age at menarche was therefore categorized into three groups: less than 12.0, 12.0--13.0, and more than 13.0 yr; the last category included those who had not yet started menstruation. Breast development stage was self-reported on postal questionnaires sent to parents at age 8 yr ([@B4]).

Assays
------

IGF-I levels were determined by RIA using a monoclonal antibody (Blood Products, Elstree, UK) and recombinant peptide (Pharmacia, Stockholm, Sweden) for standard and tracer after iodination using the chloramine-T method. Samples were analyzed after acid-acetone extraction and IGF-II saturation, and the intraassay and interassay coefficients of variation (CV) were 6.7 and 12%, respectively. IGF binding protein-1 (IGFBP-1) levels were measured by ELISA (Diagnostic Systems Laboratories, Oxford, UK) with intraassay and interassay CV of 5.3 and 5.1%, respectively. Androstenedione levels were measured by RIA (Diagnostic Systems Laboratories) with intraassay and interassay CV of 6.3 and 9.3%, respectively. Dehydroepiandrosterone sulfate (DHEAS) was assayed by immunochemiluminescence (Immulite assay; Diagnostics Products Corporation, Madrid, Spain). Intraassay and interassay CV were 5.6 and 10.1%, respectively. SHBG and leptin levels were measured using ELISA (DRG Instruments GmbH, Marburg, Germany) with interassay CV of 13 and 11.5%, respectively. Glucose was measured by the glucose oxidase method on the YSI 2300 STAT Plus analyzer (YSI Inc., Farnborough, UK). At 4.1 mmol/liter, the intraassay and interassay CV were 1.5 and 2.8%, respectively. Insulin was measured by ELISA (Diagnostic Systems Laboratories); the intraassay CV were 4.4 and 5.1% at 10.3 and 35.8 mU/liter, and equivalent interassay CV were 8.7 and 2.9%, respectively.

Statistics
----------

Differences in variables between categories of age at menarche were tested using multivariable linear regression, adjusting for exact age at the 8-yr-old baseline visit. Further models were performed, adjusting for BMI and height at 8 yr, and also excluding girls with self-reported breast development at age 8 yr. Analyses were performed using SPSS for Windows (version 15.0; SPSS Inc., Chicago, IL).

Results
=======

This report is based on a complete case analysis of the 329 girls with data on age of menarche and hormone measurements at age 8 yr (mean, 8.1 yr; range, 8.0--8.5). Earlier age at menarche was associated with greater body weight, height, and BMI at age 8 yr ([Table 1](#T1){ref-type="table"}). Before adjustment for body size, earlier menarche was associated with higher levels of IGF-I, androstenedione, DHEAS, leptin, and fasting insulin, and with lower levels of IGFBP-1and SHBG at age 8 yr (all *P* \< 0.01) ([Table 2](#T2){ref-type="table"} and Supplemental Figure 1, published on The Endocrine Society\'s Journals Online web site at <http://jcem.endojournals.org>). However, after adjustment for BMI and height at 8 yr, only IGF-I (*P* = 0.004), androstenedione (*P* = 0.01), and DHEAS (*P* = 0.01) remained associated with earlier menarche ([Table 2](#T2){ref-type="table"}). Results were similar when excluding the 30 girls with self-reported pubertal breast development. In a multivariable model, which included levels of IGF-I and adrenal androgens, BMI, and height, both IGF-I (*P* = 0.04) and androstenedione (*P* = 0.06) independently predicted earlier menarche. In sensitivity analyses, the two groups who attained menarche later (*i.e.* 12--13 *vs.* 13+ yr) also showed differences in IGF-I levels at age 8 yr (*P* = 0.02, adjusted for BMI and height).

###### 

Body size at age 8 yr by subsequent age at menarche in girls

                                 Age at menarche (yr)   *P*-trend                               
  ------------------------------ ---------------------- ------------------- ------------------- -----------
  n                              71                     74                  184                 
  Body size at 8 yr (mean)                                                                      
      Weight (kg)                30.0 (27.0--35.3)      28.0 (26.0--31.3)   26.0 (24.0--30.0)   \<0.00001
      Height (cm)                133 (130--136)         130 (126--135)      129 (125--133)      \<0.00001
      BMI (kg/m^2^)              17.0 (16.0--19.3)      16.6 (15.4--18.1)   16.1 (15.0--17.2)   \<0.00001
      Waist circumference (cm)   57 (54--63)            56 (54--61)         55 (52--58)         \<0.00001

Data are expressed as median (interquartile range). *P* values represent tests of the trends across the three age-at-menarche groups and is adjusted for age.

###### 

Hormone levels at age 8 yr by girl\'s age at menarche

                                 Age at menarche (yr)   Linear regression models[*^a^*](#TF2-1){ref-type="table-fn"}                                                                                                                                       
  ------------------------------ ---------------------- -------------------------------------------------------------- ------------------- -------------------------------------------------------- ------------------------------------------------------ ------------------------------------------------------
  n                              71                     74                                                             184                                                                                                                                 
  IGF-I (ng/ml)                  185 (132--214)         172 (121--210)                                                 149 (115--174)      6.8%, *P* \< 0.001                                       4.8%, *P* = 0.004                                      7.8%, *P* \< 0.001
  Androstenedione (ng/dl)        62.2 (42.4--86.4)      53.6 (37.4--79.7)                                              48.6 (33.8--64.8)   4.7%, *P* \< 0.001[*^b^*](#TF2-2){ref-type="table-fn"}   2.2%, *P* = 0.01[*^b^*](#TF2-2){ref-type="table-fn"}   1.9%, *P* = 0.02[*^b^*](#TF2-2){ref-type="table-fn"}
  DHEAS (μg/dl)                  29.2 (13.6--50.9)      20.9 (9.4--35.2)                                               15.9 (10.2--27.1)   6.6%, *P* \< 0.001[*^b^*](#TF2-2){ref-type="table-fn"}   1.9%, *P* = 0.01[*^b^*](#TF2-2){ref-type="table-fn"}   2.0%, *P* = 0.02[*^b^*](#TF2-2){ref-type="table-fn"}
  Fasting insulin (mU/liter)     6.9 (4.1--12.4)        5.3 (3.9--8.0)                                                 4.9 (3.3--7.8)      3.8%, *P* \< 0.001[*^b^*](#TF2-2){ref-type="table-fn"}   0.9%, *P* = 0.07[*^b^*](#TF2-2){ref-type="table-fn"}   0.8%, *P* = 0.1[*^b^*](#TF2-2){ref-type="table-fn"}
  Fasting glucose (mmol/liter)   4.9 (4.7--5.1)         4.9 (4.7--5.0)                                                 4.8 (4.6--5.0)      0.3%, *P* = 0.4                                          0.0%, *P* = 0.9                                        0.0%, *P* = 0.9
  SHBG (nmol/liter)              60.7 (37.7--76.3)      69.3 (54.8--86.7)                                              72.7 (55.1--93.3)   2.2%, *P* = 0.008                                        0.0%, *P* = 0.9                                        0.0%, *P* = 0.9
  IGFBP-1 (ng/ml)                47.8 (34.9--69.4)      55.3 (46.9--70.7)                                              62.6 (49.7--77.2)   5.1%, *P* \< 0.001                                       0.2%, *P* = 0.4                                        0.5%, *P* = 0.2
  Leptin (mmol/liter)            6.2 (3.6--13.4)        5.6 (3.6--8.3)                                                 4.4 (3.1--6.9)      5.3%, *P* \< 0.001[*^b^*](#TF2-2){ref-type="table-fn"}   0.0%, *P* = 0.8[*^b^*](#TF2-2){ref-type="table-fn"}    0.2%, *P* = 0.4[*^b^*](#TF2-2){ref-type="table-fn"}

Data are expressed as median (interquartile range) of hormone levels by age-at-menarche group. *P* values represent tests of the trends across the three age-at-menarche groups.

Variance (R-square) in age at menarche explained by hormone levels at age 8 yr. All models are adjusted for age at 8 yr.

Based on log-transformed hormone values.

Excluding 30 girls with self-reported pubertal breast development at baseline.

Discussion
==========

In a longitudinal population-based study, higher levels of IGF-I and adrenal androgens at age 8 yr were associated with earlier menarche, independent of BMI and height, suggesting that these hormones might directly promote a more rapid timing of pubertal development. Alternatively, these associations may reflect common early-life programming events that determine IGF-I levels, the timing of adrenarche, and the timing of puberty.

Reported associations between larger body size and BMI with early puberty and menarche have led to speculation of a direct role of childhood obesity on the secular trends in pubertal timing ([@B5], [@B6]). We found that body size (weight and height) and markers of body fat (BMI and waist circumference) at age 8 yr were strongly associated with earlier menarche. Some of the childhood hormonal alterations observed in girls who attained menarche earlier may therefore merely reflect these changes in body size and body composition, and we therefore adjusted for baseline height and BMI.

The GH/IGF-I axis has been causally implicated in pubertal timing because delayed puberty is a feature of rare human disorders of underactivity in this axis ([@B1]). In animal experimental models, intraventricular administration of IGF-I or IGF-I antibodies alters the timing of pubertal onset in rodents, and an increase in GnRH expression *in vitro* in the presence IGF-I and the activation of GH/IGF-I axis before the onset of pulsatile gonadotropin secretion in agonadal monkeys demonstrate a casual role of the GH/IGF-I axis in pubertal timing ([@B7], [@B8]). Our finding that circulating IGF-I levels are an independent predictor of early menarche is consistent with a reported association with IGF-I gene polymorphisms and suggests a direct role of IGF-I in pubertal timing in humans ([@B9]). IGF-I may modulate the reproductive system through widespread effects on hypothalamus, pituitary, and ovaries by its endocrine, paracrine, and autocrine actions based on the developmental and hormonal state ([@B10]). Furthermore, IGF-I plays a role in ovarian follicular formation and enhances FSH-mediated steroidogenesis ([@B9]).

Traditionally, adrenarche and gonadarche are considered to be separate processes; however, studies of girls with congenital adrenal hyperplasia or premature adrenarche suggest a direct role of adrenal androgens in initiating puberty in those disorders ([@B11]). Our findings indicate a possible role of adrenal androgens in pubertal timing in healthy children. Although the mechanisms are not certain, circumstantial evidence suggests that adrenal androgens may potentially reduce the inhibitory feedback from gonadal steroids, leading to increased GnRH pulsatility ([@B11]). Androstenedione is secreted from the ovary as well as from the adrenal gland, and consequently, its levels are higher in girls than in boys after age 8 yr ([@B12]). Hence, ovarian androgens may also play a role in pubertal timing in girls.

All of the other hormones we studied were also strongly associated with menarche timing, but these associations were attenuated after adjustment for baseline body size. Although such hormones could therefore be only "passive markers" of larger body size, it is still possible that some of these hormones might actively mediate the effects of larger body size on earlier menarche. Leptin, an adipocyte-derived hormone closely correlated with fat mass, has been implicated in signaling to the hypothalamus about body weight and energy balance. Although, initial observations suggested a direct role of leptin in inducing puberty, subsequently further data from animal studies, human observations of a steady rise with age rather than any rapid surge in levels before puberty, and reports that recombinant leptin treatment increases GnRH pulsatility in older, but not in younger, leptin-deficient children together suggest only a permissive role of leptin in regulating pubertal timing ([@B1], [@B2]).

Insulin resistance and subsequent hyperinsulinemia associated with childhood obesity are thought to play a mediating role in the development of early puberty ([@B5]). Increased insulin levels reduce levels of SHBG and IGFBP-1, which in turn leads to greater bioavailability of sex steroids and IGF-I, respectively ([@B13], [@B14]). In addition to the findings from observational studies, a causal role of insulin in puberty timing is supported by randomized controlled trials of metformin, which reduced the circulating hyperinsulinemia and prevented early pubertal onset and early menarche in girls with premature pubarche ([@B15]).

Recently reported associations of thinness at birth and early catch-up weight gain with earlier menarche ([@B16], [@B17]) suggest a key role of developmental programming resulting from prenatal and early postnatal environmental exposures in influencing the future tempo of growth and pubertal development. Higher levels of IGF-I at age 5 yr are seen in those children with lower birth weights and faster infancy weight gain, even independent of their current body composition ([@B18]). Similarly, both low birth weight and early postnatal catch-up weight gain are also associated with higher levels of adrenal androgens at age 8 yr, independent of body size ([@B19], [@B20]). Our findings now link these childhood hormonal alterations with early menarche and suggest that these hormones are involved in the developmental programming pathways that influence childhood growth and pubertal development. Alternatively, these hormonal changes may simply represent markers of common developmental pathways, and further evidence from intervention studies or genetic causal modeling is needed to confirm the causal relationships.

It is possible that higher IGF-I and adrenal androgen levels were simply markers of those girls who were already in early puberty at age 8 yr. However, our findings were unchanged after excluding those with self-reported breast development, and we also found differences in IGF-I levels at age 8 yr between the two groups of girls attaining menarche at 12--13 *vs.* 13+, at least 4 yr later, suggesting that these changes are not simply due to early pubertal activation at age 8 yr. Further studies of hormone levels at younger ages, possibly using ultrasensitive assays, would help to distinguish the effects of prepubertal hormone levels on the onset and progression of puberty.

In conclusion, in a longitudinal population-based study, we found that higher circulating levels of IGF-I and adrenal androgens at age 8 yr were related to earlier menarche, independent of body size. These findings support direct roles of these hormones on the regulation of pubertal maturation.

Abbreviations: BMIBody mass indexCVcoefficient of variationDHEASdehydroepiandrosterone sulfateIGFBP-1IGF binding protein-1.
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